This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Researchers suggest all diabetes patients on weight-loss drugs should be regularly screened and monitored for potential eye ...

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...